Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco Pharma, in alliance with Lupin, received US FDA approval for Eribulin Mesylate Injection, 1 mg/2ml. This drug is bioequivalent to Halaven® Injection, which had estimated annual US sales of USD 43.7 million.
Jun 03 2026 11:14:03
Natco Pharma Limited
Natco Pharma has filed the transcript of its Q4 FY26 earnings conference call, held on May 29, 2026. This provides investors with a detailed record of the discussion and Q&A session.
May 30 2026 12:19:57
Natco Pharma Q4 Results: Stock falls 9% as revenue drops 40%, margin shrinks
Natco Pharma reported a substantial decline in its Q4 performance, with revenue dropping by 40% and margins shrinking, which led to a fall in the company's stock price.
May 29 2026 14:39:42
Natco Pharma Ltd - 524816 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March, 2026
Natco Pharma's FY26 consolidated revenue declined 8.5% to ₹4,375.9 Cr, with net profit falling 24.7% to ₹1,418.5 Cr. This includes a ₹115 Cr one-time tax benefit from moving to a new tax regime. The board also approved the demerger of its Agro Chemical business.
May 29 2026 14:16:42
Natco Pharma Ltd - 524816 - Board Meeting Intimation for Considering Audited Financial Results For The Financial Year Ended 31St March, 2026
Natco Pharma Ltd board will meet on May 29, 2026, to approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will also discuss other related business matters.
May 18 2026 16:38:09
Read More